SiBone (NASDAQ:SIBN) Given Average Rating of "Moderate Buy" by Brokerages

SiBone (NASDAQ:SIBN) has received a "Moderate Buy" rating from analysts, with one sell and four buy recommendations. The average target price is $23.00. Recent insider sales include Director Jeffrey W. Dunn selling 80,000 shares and SVP Michael A. Pisetsky selling 3,328 shares. Institutional investors have been active, with 98.11% ownership. SiBone's stock opened at $18.87, with a market cap of $818.77 million. The company reported better-than-expected earnings for the quarter.

SiBone (NASDAQ:SIBN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $23.00.

4 Recent Earnings Winners Riding Fresh Momentum in May

A number of equities research analysts have recently issued reports on SIBN shares. Wall Street Zen lowered SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Morgan Stanley reaffirmed an "overweight" rating and set a $23.00 price objective on shares of SiBone in a research note on Tuesday. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an "overweight" rating in a report on Monday, August 11th. Truist Financial dropped their target price on shares of SiBone from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, October 15th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of SiBone in a research report on Tuesday, November 25th.

Check Out Our Latest Report on SiBone

Insider Activity at SiBone

In other news, Director Jeffrey W. Dunn sold 80,000 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $18.95, for a total value of $1,516,000.00. Following the completion of the sale, the director owned 10,307 shares in the company, valued at $195,317.65. This represents a 88.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Pisetsky sold 3,328 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $17.41, for a total value of $57,940.48. Following the completion of the sale, the senior vice president directly owned 251,896 shares of the company's stock, valued at approximately $4,385,509.36. This trade represents a 1.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 127,128 shares of company stock worth $2,311,652. Insiders own 3.90% of the company's stock.

Institutional Investors Weigh In On SiBone

A number of institutional investors have recently bought and sold shares of SIBN. State of Alaska Department of Revenue acquired a new position in shares of SiBone in the 3rd quarter valued at about $39,000. State of Wyoming acquired a new stake in shares of SiBone during the second quarter worth approximately $55,000. Canada Pension Plan Investment Board purchased a new position in SiBone during the second quarter valued at approximately $68,000. Virtus Advisers LLC acquired a new position in SiBone in the 1st quarter valued at approximately $58,000. Finally, Quarry LP increased its stake in SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company's stock valued at $72,000 after buying an additional 4,356 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SiBone Trading Down 3.0%

Shares of NASDAQ:SIBN opened at $18.87 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The stock has a market capitalization of $818.77 million, a price-to-earnings ratio of -37.00 and a beta of 0.75. SiBone has a 1-year low of $12.49 and a 1-year high of $20.05. The company has a 50 day moving average price of $16.12 and a 200 day moving average price of $16.82.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The company had revenue of $48.66 million for the quarter, compared to analysts' expectations of $46.67 million. SiBone has set its FY 2025 guidance at EPS. On average, research analysts anticipate that SiBone will post -0.78 EPS for the current fiscal year.

About SiBone

(Get Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Should You Invest $1,000 in SiBone Right Now?

Before you consider SiBone, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.

While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here